Portfolio

As of January 1st, 2022

Click on project to learn more

Preclinical Launched after the development of the prototype, preclinical development includes a series of studies and operations aimed at confirming the product's viability, testing its safety and establishing the scientific bases and regulatory strategy necessary for all applications for clinical trial approval.

mdc-ANG

Schizophrenia

mdc-TTG

Covid-19
Ivermectin

mdc-GRT

Organ Transplant
Tacrolimus

mdc-WWM

Contraception
Progestin (non-MPA)

mdc-STM

Malaria
Ivermectin

mdc-KPT

Pain
(Animal health)

Clinical phase 1-2 Phase 1 includes healthy volunteers to assess their tolerance to the treatment. Phase 2 is carried with a limited group of sick patients to assess the treatment's efficacy, the drug's optimal dose and any side effects.

mdc-TJK

Schizophrenia
Olanzapine

mdc-CWM

Post-op pain
Celecoxib

Clinical phase 3 Phase 3 is undertaken with a large number of sick patients to compare the treatment's efficacy to that of a placebo or a standard of care. If successful, this is the final step before the filing for marketing authorization.

NDA Bringing a drug on the market is subject to prior authorization from health authorities such as the FDA (Federal Drug Administration) in the United States and EMA (European Medicines Agency) in Europe. The application for the marketing authorization (NDA) is based on document compiling data from the work carried out during the development of the product.

mdc-IRM

Schizophrenia
Risperidone

Market Once all the stages of development and approval have been received by the health authorities, the product is marketed.

In partnership with Teva Pharmaceuticals

In partnership with AIC

Internal programs

Supported by the Bill & Melinda Gates Foundation

Supported by Unitaid

Animal Health product (different clinical development process)

Portfolio extension

We have designed a structured approach to identify new opportunities and enlarge our portfolio of proprietary and partnered products. This assessment process aims to identify unmet needs in a large panel of indications that could be met with long acting injectable treatments and identify the most compatible APIs with our technology. This preliminary step is essential to significantly increase the likelihood of success for each product entering formulation stage.

Session en français

Rendez-vous le mardi 14 juin à 18h30 (CEST) pour une vidéoconférence dédiée aux résultas annuel 2021-2022

English session

On Tuesday 14, June at 7.30 pm (CEST) participate in our videoconference dedicated to our Financial year 2021-2022 results

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.